In summary, KRX-104130, an MCHR1 antagonist that overcame cardiotoxicity, could regulate liver levels by inducing an increase in LDLR, which is involved in cholesterol regulation and provides helpful clues for NASH treatment. This evidence concerns the gene MCHR1 and metabolic dysfunction-associated steatohepatitis.